Number of the records: 1
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine
- 1.
SYSNO ASEP 0365072 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine Author(s) Mikyšková, Romana (UMG-J) RID
Indrová, Marie (UMG-J) RID
Šímová, Jana (UMG-J) RID
Bieblová, Jana (UMG-J)
Bubeník, Jan (UMG-J)
Reiniš, Milan (UMG-J) RIDSource Title Oncology Reports - ISSN 1021-335X
Roč. 25, č. 6 (2011), s. 1683-1689Number of pages 7 s. Language eng - English Country GR - Greece Keywords gemcitabine ; human papilloma virus ; interleukin 12 ; lung metastases ; cellular vaccines ; immunotherapy Subject RIV EB - Genetics ; Molecular Biology R&D Projects GA301/09/1024 GA ČR - Czech Science Foundation (CSF) GA301/07/1410 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50520514 - UMG-J (2005-2011) UT WOS 000290649600027 DOI 10.3892/or.2011.1221 Annotation Genetically modified tumour cells producing cytokines such as IL-12 are potent activators of antitumour immune responses and a promising therapeutic modality when combined with chemotherapy. We examined whether IL-12-producing cellular vaccines can augment chemotherapy of HPV 16-associated murine tumours with cytostatic agent gemcitabine (GEM). Peritumoral administration of IL-12-producing tumour vaccines enhanced the effect of cytoreductive therapy with GEM in non-metastasizing murine carcinoma TC-1 and in metastasizing murine carcinoma MK16. Lung metastases in mice were substantially decreased. In surgical minimal residual tumour disease IL-12-producing tumour vaccine and GEM after MK16 tumour surgery also reduced tumour recurrences and metastases. Tumour inhibitory effects of GEM plus IL-12 were associated with high production of interferon-γ by splenocytes. IL-12-producing vaccine can thus enhance the effect of GEM chemotherapy in some HPV16-associated murine tumour models. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2012
Number of the records: 1